
CDTX
Cidara Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
63.880
Open
61.930
VWAP
--
Vol
293.55K
Mkt Cap
1.25B
Low
61.185
Amount
--
EV/EBITDA(TTM)
--
Total Shares
4.56M
EV
1.08B
EV/OCF(TTM)
--
P/S(TTM)
--
Cidara Therapeutics, Inc. is a biotechnology company. The Company is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The Company is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
0.00
-100%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Cidara Therapeutics, Inc. (CDTX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 195.86%.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
Stock Price
Go Up

+195.86%
In Past 3 Month
7 Analyst Rating

-4.24% Downside
Wall Street analysts forecast CDTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDTX is 59.17 USD with a low forecast of 45.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy

-4.24% Downside
Current: 61.790

Low
45.00
Averages
59.17
High
75.00

-4.24% Downside
Current: 61.790

Low
45.00
Averages
59.17
High
75.00
Guggenheim
Buy
maintain
$68 -> $69
2025-07-09
Reason
Guggenheim
Price Target
$68 -> $69
2025-07-09
maintain
Buy
Reason
Guggenheim raised the firm's price target on Cidara Therapeutics to $69 from $68 and keeps a Buy rating on the shares. Guggenheim updated its model following Cidara's recent equity raise and the NAVIGATE Phase 2b data, which provided critical validation of CD388 as a compelling flu prevention option, the analyst tells investors in a research note. A potential BARDA funding decision offers additional upside optionality as early as September 2025, the firm says.
RBC Capital
Outperform
maintain
$35 -> $75
2025-06-24
Reason
RBC Capital
Price Target
$35 -> $75
2025-06-24
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Cidara Therapeutics to $75 from $35 and keeps an Outperform rating on the shares. The firm notes that the company's "best-case" Phase 2Ib data sets the stage for lead drug CD388 to potentially be a novel, universal long-acting flu preventative combining and improving upon properties of current vaccines and prophylactics and potentially transforming the space, the analyst tells investors in a research note. Shares have appreciated on Monday's news, but given the program's now meaningful efficacy and safety de-risking and the $3B ultimate opportunity, a higher valuation is warranted, RBC added.
Guggenheim
Buy
upgrade
$50 -> $68
2025-06-24
Reason
Guggenheim
Price Target
$50 -> $68
2025-06-24
upgrade
Buy
Reason
Guggenheim raised the firm's price target on Cidara Therapeutics to $68 from $50 and keeps a Buy rating on the shares, stating that the NAVIGATE Phase 2b data "reflect striking efficacy" and a clean safety profile. With results exceeding the firm's bull case scenario and providing critical validation of CD388 as "a compelling flu prevention option," the firm believes CD388 has "clear blockbuster potential," the analyst tells investors.
RBC Capital
Outperform
maintain
$35 -> $75
2025-06-23
Reason
RBC Capital
Price Target
$35 -> $75
2025-06-23
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Cidara Therapeutics to $75 from $35 and keeps an Outperform rating on the shares. Positive Phase IIb results position Cidara's lead drug CD388 as a potential groundbreaking, long-acting flu preventative that could combine and enhance the benefits of existing vaccines and prophylactics, potentially reshaping the prevention landscape, the analyst tells investors in a research note. The firm would buy shares on the strength, given the program's now meaningful efficacy and safety de-risking and $3B ultimate opportunity.
H.C. Wainwright
H.C. Wainwright
initiated
$41
2025-06-19
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$41
2025-06-19
initiated
Reason
H.C. Wainwright assumed coverage of Cidara Therapeutics with a Buy rating and $41 price target. Cidara is developing CD388, the company's lead influenza drug-Fc conjugate candidate in development for the prevention of all strains of influenza A and B, the analyst tells investors in a research note. The firm says that with a high unmet need, current influenza vaccines and antivirals don't adequately protect against high risk patient populations.
RBC Capital
Outperform
maintain
$31 -> $35
2025-05-23
Reason
RBC Capital
Price Target
$31 -> $35
2025-05-23
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Cidara Therapeutics to $35 from $31 and keeps an Outperform rating on the shares. Following the company's virtual R&D day, the firm has come away impressed by the thoroughly mapped-out blueprint, covering NAVIGATE's enhanced statistical plan, potential phase 3 trial design, the strategy to drive CD388's commercial effectiveness as well as government stockpiling potential, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Cidara Therapeutics Inc (CDTX.O) is -8.70, compared to its 5-year average forward P/E of -2.97. For a more detailed relative valuation and DCF analysis to assess Cidara Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-2.97
Current PE
-8.70
Overvalued PE
2.42
Undervalued PE
-8.36
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-0.23
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.14
Undervalued EV/EBITDA
-1.60
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
59.88
Current PS
0.00
Overvalued PS
268.95
Undervalued PS
-149.18
Financials
Annual
Quarterly
FY2025Q1
YoY :
-100.00%
0.00
Total Revenue
FY2025Q1
YoY :
+136.36%
-25.27M
Operating Profit
FY2025Q1
YoY :
+127.39%
-23.48M
Net Income after Tax
FY2025Q1
YoY :
-27.19%
-1.66
EPS - Diluted
FY2025Q1
YoY :
+229.23%
-21.95M
Free Cash Flow
FY2025Q1
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q1
YoY :
-100.00%
N/A
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
75.5K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
21.3K
USD
2
Bought
0-3
3
100.1M
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
4
963.0K
Volume
Months
6-9
5
3.2M
Volume
Months
0-12
2
1.4M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
75.5K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
21.3K
USD
2
Bought
0-3
3
100.1M
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CDTX News & Events
Events Timeline
2025-06-30 (ET)
2025-06-30
08:18:07
Cidara Therapeutics announces inclusion in Russell 2000, 3000 Indexes

2025-06-24 (ET)
2025-06-24
20:51:26
Cidara Therapeutics 7.95M share Secondary priced at $44.00

2025-06-23 (ET)
2025-06-23
16:17:09
Cidara Therapeutics announces $250M common stock offering

Sign Up For More Events
Sign Up For More Events
News
2.0
07-20NASDAQ.COMATAI Impresses, CDTX Navigates With Confidence, MTSR Builds Momentum, COGT Keeps Scaling The Summit…
9.0
06-30NewsfilterCidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
8.5
06-26NewsfilterCidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Sign Up For More News
People Also Watch

ANIK
Anika Therapeutics Inc
8.100
USD
-27.42%

VSTM
Verastem Inc
6.230
USD
-0.95%

FF
FutureFuel Corp
4.110
USD
-1.20%

CLBR
Colombier Acquisition Corp II
0
USD
+1.62%

RAIL
FreightCar America Inc
10.200
USD
-1.07%

BWFG
Bankwell Financial Group Inc
38.740
USD
-1.68%

PKBK
Parke Bancorp Inc
20.800
USD
-2.39%

TSBK
Timberland Bancorp Inc
31.780
USD
-1.15%

FET
Forum Energy Technologies Inc
20.160
USD
-2.51%

AOMR
Angel Oak Mortgage REIT Inc
9.370
USD
-0.95%
FAQ

What is Cidara Therapeutics Inc (CDTX) stock price today?
The current price of CDTX is 61.79 USD — it has decreased -0.23 % in the last trading day.

What is Cidara Therapeutics Inc (CDTX)'s business?

What is the price predicton of CDTX Stock?

What is Cidara Therapeutics Inc (CDTX)'s revenue for the last quarter?

What is Cidara Therapeutics Inc (CDTX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Cidara Therapeutics Inc (CDTX)'s fundamentals?

How many employees does Cidara Therapeutics Inc (CDTX). have?
